María Inés Pérez-Millán

Dr. María Inés Pérez-Millán

Institute of Biomedical Investgations (UBA-CONICET), University of Buenos Aires, Buenos Aires, Argentina
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2016 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
QFQing Fang
Qing Fang
AGAkima S. George
Akima S. George
MBMichelle L. Brinkmeier
Michelle L. Brinkmeier
AMAmanda H. Mortensen
Amanda H. Mortensen
PGPeter Gergics
Peter Gergics
SCSally Camper
Sally Camper
The genetic basis for combined pituitary hormone deficiency (CPHD) is complex, involving 30 genes in a variety of syndromic and nonsyndromic presentations. Molecular diagnosis of this disorder is valuable for predicting disease progression, avoiding unnecessary surgery, and family planning. We expect that the application of high throughput sequencing will uncover additional contributing genes and eventually become a valuable tool for molecular diagnosis. For example, in the last 3 years, six new genes have been implicated in CPHD using whole-exome sequencing. In this review, we present a historical perspective on gene discovery for CPHD and predict approaches that may facilitate future gene identification projects conducted by clinicians and basic scientists. Guidelines for systematic reporting of genetic variants and assigning causality are emerging. We apply these guidelines retrospectively to reports of the genetic basis of CPHD and summarize modes of inheritance and penetrance for each of the known genes. In recent years, there have been great improvements in databases of genetic information for diverse populations. Some issues remain that make molecular diagnosis challenging in some cases. These include the inherent genetic complexity of this disorder, technical challenges like uneven coverage, differing results from variant calling and interpretation pipelines, the number of tolerated genetic alterations, and imperfect methods for predicting pathogenicity. We discuss approaches for future research in the genetics of CPHD.

1 January 2013
Verified
Book Chapter
Closed access
SDShannon W. Davis
Shannon W. Davis
BEBuffy S. Ellsworth
Buffy S. Ellsworth
MPMaría Inés Pérez-Millán
María Inés Pérez-Millán
PGPeter Gergics
Peter Gergics
VSVanessa Schade
Vanessa Schade
SCSally Camper
Sally Camper

26 January 2016 in Endocrinology
Verified
Journal Article
Open access
PDF file
SDShannon W. Davis
Shannon W. Davis
JKJessica L. Keisler
Jessica L. Keisler
MPMaría Inés Pérez-Millán
María Inés Pérez-Millán
VSVanessa Schade
Vanessa Schade
SCSally Camper
Sally Camper
Mutations in PROP1, the most common known cause of combined pituitary hormone deficiency in humans, can result in the progressive loss of all hormones of the pituitary anterior lobe. In mice, Prop1 mutations result in the failure to initiate transcription of Pou1f1 (also known as Pit1) and lack somatotropins, lactotropins, and thyrotropins. The basis for this species difference is unknown. We hypothesized that Prop1 is expressed in a progenitor cell that can develop into all anterior lobe cell types, and not just the somatotropes, thyrotropes, and lactotropes, which are collectively known as the PIT1 lineage. To test this idea, we produced a transgenic Prop1-cre mouse line and conducted lineage-tracing experiments of Prop1-expressing cells. The results reveal that all hormone-secreting cell types of both the anterior and intermediate lobes are descended from Prop1-expressing progenitors. The Prop1-cre mice also provide a valuable genetic reagent with a unique spatial and temporal expression for generating tissue-specific gene rearrangements early in pituitary gland development. We also determined that the minimal essential sequences for reliable Prop1 expression lie within 10 kilobases of the mouse gene and demonstrated that human PROP1 can substitute functionally for mouse Prop1. These studies enhance our understanding of the pathophysiology of disease in patients with PROP1 mutations.

28 June 2016 in eLife
Verified
Journal Article
Open access
MPMaría Inés Pérez-Millán
María Inés Pérez-Millán
MBMichelle L Brinkmeier
Michelle L Brinkmeier
AMAmanda H Mortensen
Amanda H Mortensen
SCSally Camper
Sally Camper
Mutations in PROP1 are the most common cause of hypopituitarism in humans; therefore, unraveling its mechanism of action is highly relevant from a therapeutic perspective. Our current understanding of the role of PROP1 in the pituitary gland is limited to the repression and activation of the pituitary transcription factor genes Hesx1 and Pou1f1, respectively. To elucidate the comprehensive PROP1-dependent gene regulatory network, we conducted genome-wide analysis of PROP1 DNA binding and effects on gene expression in mutant mice, mouse isolated stem cells and engineered mouse cell lines. We determined that PROP1 is essential for stimulating stem cells to undergo an epithelial to mesenchymal transition-like process necessary for cell migration and differentiation. Genomic profiling reveals that PROP1 binds to genes expressed in epithelial cells like Claudin 23, and to EMT inducer genes like Zeb2, Notch2 and Gli2. Zeb2 activation appears to be a key step in the EMT process. Our findings identify PROP1 as a central transcriptional component of pituitary stem cell differentiation.

15 May 2010 in Endocrine Pathology
Verified
Journal Article
Closed access
PDF file
CCCarolina Cristina
Carolina Cristina
MPMaría Inés Pérez-Millán
María Inés Pérez-Millán
GLGuillermina Luque
Guillermina Luque
RDRaúl Ariel Dulce
Raúl Ariel Dulce
GSGustavo Sevlever
Gustavo Sevlever
DBDamasia Becu-Villalobos
Damasia Becu-Villalobos

23 October 2010 in Neuroendocrinology
Verified
Journal Article
Open access
PDF file
IGIsabel Garcia-Tornadú
Isabel Garcia-Tornadú
MPMaría Inés Pérez-Millán
María Inés Pérez-Millán
VRVictoria Recouvreux
Victoria Recouvreux
MRMaria Cecilia Ramirez
Maria Cecilia Ramirez
GLGuillermina Luque
Guillermina Luque
DBDamasia Becu-Villalobos
Damasia Becu-Villalobos
Dopamine D2 receptor (D2R) participation in prolactin regulation is well documented, but the role of D2Rs in the control of other hormones involved in growth, food intake and glucose metabolism has not been extensively studied. The study of D2R knockout mice (Drd2–/–) puts forward new insights into the role of the D2R in growth hormone (GH)-releasing hormone-GH regulation, peptides involved in food intake, glucose homeostasis, as well as in prolactinoma development. The expected phenotype of chronic hyperprolactinemia and prolactinoma development was found in the Drd2–/– mouse, and this model constitutes a valuable tool in the study of dopamine-resistant prolactinomas. Unexpectedly, these mice were growth retarded, and the importance of functional hypothalamic D2Rs in the neonatal period was revealed. In the Drd2–/– mouse there was a failure of high neonatal GH levels and therefore the expansion of pituitary somatotropes was permanently altered. These mice also had increased food intake, and a sexually dimorphic participation of the D2R in food intake regulation is suggested. The effect described is probably secondary to D2R regulation of prolactin secretion. Furthermore, the negative modulation of D2Rs on α-melanocyte-stimulating hormone release and positive action on the hypothalamic expression of orexins reveals the complex D2R regulation of food intake. Finally, pancreatic D2Rs inhibit glucose-stimulated insulin release. Lack of dopaminergic inhibition throughout development in the Drd2–/– mouse may exert a gradual deteriorating effect on insulin homeostasis, so that eventually glucose intolerance develops. These results highlight the complex endocrine actions of the D2Rs at different levels, hypothalamus, pituitary or pancreas, which function to improve fitness, reproductive success and survival.